- document
-
Liu, J. (author), O'Brien, K.L. (author), Lynch, D.M. (author), Simmons, N.L. (author), La Porte, A. (author), Riggs, A.M. (author), Abbink, P. (author), Coffey, R.T. (author), Grandpre, L.E. (author), Seaman, M.S. (author), Landucci, G. (author), Forthal, D.N. (author), Montefiori, D.C. (author), Carville, A. (author), Mansfield, K.G. (author), Havenga, M.J. (author), Pau, M.G. (author), Goudsmit, J. (author), Barouch, D.H. (author), TNO Kwaliteit van Leven (author)A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a phase 2b efficacy study in humans. Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus...article 2009
- document
-
Koudstaal, W. (author), Hartgroves, L. (author), Havenga, M. (author), Legastelois, I. (author), Ophorst, C. (author), Siewerts, M. (author), Zuijdgeest, D. (author), Vogels, R. (author), Custers, J. (author), de Boer-Luijtze, E. (author), de Leeuw, O. (author), Cornelissen, L. (author), Goudsmit, J. (author), Barclay, W. (author), TNO Kwaliteit van Leven (author)Reverse genetics, the generation of influenza viruses from cDNA, presents a rapid method for creating vaccine strains. The technique necessitates the use of cultured cells. Due to technical and regulatory requirements, the choice of cell lines for production of human influenza vaccines is limited. PER.C6® cells, among the most extensively...article 2009
- document
-
Pant, N. (author), Hultberg, A. (author), Zhao, Y. (author), Svensson, L. (author), Pan-Hammarström, Q. (author), Johansen, K. (author), Pouwels, P.H. (author), Ruggeri, F.M. (author), Hermans, P. (author), Frenken, L. (author), Borén, T. (author), Marcotte, H. (author), Hammarström, L. (author), TNO Preventie en Gezondheid (author)Background. Rotavirus-induced diarrhea poses a worldwide medical problem in causing substantial morbidity and mortality among children in developing countries. We therefore developed a system for passive immunotherapy in which recombinant lactobacilli constitutively express neutralizing variable domain of llama heavy-chain (VHH) antibody...article 2006
- document
-
TNO Kwaliteit van Leven (author), Lemckert, A.A.C. (author), Grimbergen, J. (author), Smits, S. (author), Hartkoorn, E. (author), Holterman, L. (author), Berkhout, B. (author), Barouch, D.H. (author), Vogels, R. (author), Quax, P. (author), Goudsmit, J. (author), Havenga, M.J.E. (author)Recombinant adenoviral vectors based on type 5 (rAd5) show great promise as a vaccine carrier. However, neutralizing activity against Ad5 is prevalent and high-titred among human populations, and significantly dampens Ad5-based vaccine modalities. The generation of alternative adenoviral vectors with low seroprevalence thus receives much...article 2006
- document
-
Vogels, R. (author), Zuijdgeest, D. (author), van Rijnsoever, R. (author), Hartkoorn, E. (author), Damen, I. (author), de Béthune, M.-P. (author), Kostense, S. (author), Penders, G. (author), Helmus, N. (author), Koudstaal, W. (author), Cecchini, M. (author), Wetterwald, A. (author), Sprangers, M. (author), Lemckert, A. (author), Ophorst, O. (author), Koel, B. (author), van Meerendonk, M. (author), Quax, P. (author), Panitti, L. (author), Grimbergen, J. (author), Bout, A. (author), Goudsmit, J. (author), Havenga, M. (author)Replication-deficient human adenovirus type 5 (Ad5) can be produced to high titers in complementing cell lines, such as PER.C6, and is widely used as a vaccine and gene therapy vector. However, preexisting immunity against Ad5 hampers consistency of gene transfer, immunological responses, and vector-mediated toxicities. We report the...article 2003
- document
-
TNO Preventie en Gezondheid (author), Chargelegue, D. (author), Obeid, O.E. (author), Hsu, S.C. (author), Shaw, M.D. (author), Denbury, A.N. (author), Taylor, G. (author), Steward, M.W. (author)Respiratory syncytial virus (RSV) is the most important cause of bronchiolitis and pneumonia in infants and young children worldwide. As yet, there is no effective vaccine against RSV infection, and previous attempts to develop a formalin-inactivated vaccine resulted in exacerbated disease in recipients subsequently exposed to the virus. In the...article 1998
- document
-
Chargelegue, D. (author), Obeid, O.E. (author), Shaw, D.M. (author), Denbury, A.N. (author), Hobby, P. (author), Hsu, S.C. (author), Steward, M.W. (author), TNO Preventie en Gezondheid (author)Aims: To identify peptides that mimic (mimotopes) conformational and protective epitopes of RSV fusion protein and to assess their efficacy as immunogens and potential vaccines. Material and methods: An 8-mer solid- phase (TG resin) library was screened with a neutralising and protective RSV fusion protein specific monoclonal antibodies (Mab-19)...article 1997
- document
-
Remarque, E.J. (author), Nijhuis, E.W.P. (author), Hinloopen, B. (author), Nagelkerken, L. (author), van der Velde, E.A. (author), Ligthart, G.J. (author), Instituut voor Experimentele Gerontologie TNO (author)To investigate the effects of the altered composition of the helper T cell compartment in ageing on the humoral response to influenza vaccine, we investigated correlations between helper T cell subsets and anti-influenza antibody responses in 23 JUNIEUR healthy young and 41 SENIEUR healthy elderly subjects. Naive helper T cell numbers (CD4...article 1996
- document
-
Dobber, R. (author), Tielemans, M. (author), Nagelkerken, L. (author), TNO Preventie en Gezondheid (author)In the present study we investigated whether age-related changes in the composition and functional properties of murine CD4+ T cells are reflected in vivo by a changed humoral response to influenza vaccine in aged mice. After the primary immunization, the titers of influenza-specific IgM, IgG1, IgG2a, and IgG2b, but not of IgG3 and IgE, were...article 1995
- document
-
Radl, J. (author), Hoogeveen, C.M. (author), van den Wall Bake, A.W.L. (author), Mestecky, J. (author), Instituut voor verouderings- en vaatziekten onderzoek TNO (author)Chemicals/CAS: hemagglutinin, 37333-12-3; sialidase, 9001-67-6; Antibodies, Monoclonal; Antibodies, Viral; Hemagglutinins, Viral; Immunoglobulin A; Immunoglobulin G; Influenza Vaccine; Neuraminidase, EC 3.2.1.18article 1995
- document
- Schaapveld, K. (author), Hirasing, R.A. (author), Jol-Japin, W.F. (author), TNO Preventie en Gezondheid (author) article 1992
- document
-
Stitz, L. (author), Kreeftenberg, J.G. (author), Loggen, H.G. (author), Balner, H. (author), Primatencentrum TNO (author)62 Rhesus monkeys were tested at different times after vaccinia virus infection for virus-specific induction of lymphocyte proliferation in vitro or antibody production in vivo. No association was found between identifiable RhLA-controlled antigens and the strength of the cellular proliferative and/or humoral response. Chemicals/CAS: Antibodies,...article 1981
- document
-
Schellekens, H. (author), Weimar, W. (author), de Reus, A. (author), Bolhuis, R.L.H. (author), Cantell, K. (author), Instituut voor Experimentele Gerontologie TNO (author)Chemicals/CAS: Adjuvants, Immunologic; Antibodies, Viral; Interferons, 9008-11-1article 1981